Dr. Jagan Pillai, Cleveland Clinic Lou Ruvo Center for Brain Health and CWRU and falls under the umbrella of research conducted by the Cleveland Alzheimer’s Disease Research Center (CADRC). His research study just started, September 2022, and will valuate immune cell activation and blood brain barrier(BBB) changes at different stage of Alzheimer’s disease.

This will help develop therapeutic targeting of specific immune and BBB changes at the most effective clinical stage of Alzheimer’s disease to make a useful clinical impact in overcoming cognitive decline.

The results from this study will enable the identification of novel mechanisms that regulate immune cells in the periphery and the central nervous system, and the state of blood brain barrier among Alzheimers disease patients and among normal control subjects. This will help provide potential means to manipulate these immune cells for therapeutic purposes to overcome Alzheimer’s disease in the future.